2,420 results match your criteria: "European Institute of Oncology - IRCCS[Affiliation]"
Trials
October 2024
Gastroenterology Department, Balmis General University Hospital, ISABIAL, Alicante, Dr, Spain.
Background: Some evidence suggests that fluid resuscitation with lactated Ringer's solution (LR) may have an anti-inflammatory effect on acute pancreatitis (AP) when compared to normal saline (NS) and may be associated with a decrease in severity, but existing single-center randomized controlled trials showed conflicting results. The WATERLAND trial aims to investigate the efficacy and safety of fluid resuscitation using LR compared to NS in patients with AP.
Methods: The WATERLAND trial is an international multicenter, open-label, parallel-group, randomized, controlled, superiority trial.
J Eur Acad Dermatol Venereol
October 2024
Department of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milano, Italy.
Leukemia
October 2024
Institute for Cancer Genetics, Columbia University, New York, NY, USA.
Br J Radiol
December 2024
Breast Imaging Division, IEO European Institute of Oncology IRCCS, Milan, Italy.
Objectives: This meta-analysis compares the efficacy, limitations, and clinical implications of abbreviated breast MRI (AB-MRI) and full protocol MRI (FP-MRI), focusing on diagnostic accuracy across diverse populations. It extends previous analyses by including studies conducted after 2019 in both screening and diagnostic contexts.
Methods: We conducted a systematic review (November 2019 to December 2022), using a bivariate model to calculate summary estimates of sensitivity and specificity.
Radiol Med
November 2024
Radiation Oncology Unit, Department of Experimental and Clinical Biomedical Sciences, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.
J Endocrinol Invest
October 2024
Nuclear Medicine Department, Foundation IRCCS, Istituto Nazionale Tumori, Milan, Italy.
Eur Urol
October 2024
Onkozentrum Zurich, University of Zurich and Tumorzentrum Hirslanden Zurich, Zurich, Switzerland.
Gynecol Oncol
December 2024
Gynecologic Oncology Centre, Department of Gynecology, Obstetrics and Neonatology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic. Electronic address:
Background: The aim was to evaluate the performance of the Peritoneal Cancer Index (PCI) using imaging (ultrasound, contrast-enhanced computed tomography (CT), and whole-body diffusion-weighted magnetic resonance imaging (WB-DWI/MRI) in assessing peritoneal carcinomatosis and predicting non-resectability in tubo-ovarian carcinoma patients.
Methods: This was a prospective multicenter observational study. We considered all patients with suspected primary ovarian/tubal/peritoneal cancer who underwent preoperative ultrasound, CT, and WB-DWI/MRI (if available).
Front Oncol
September 2024
Division of Medical Senology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Introduction: Several studies have demonstrated that, following a breast cancer (BC) diagnosis, patients are eager to obtain information on cancer and nutrition, in order to ameliorate both their quality of life (QoL) and disease outcome. To avoid BC survivors to get wrong information from unreliable sources, healthcare providers need to be aware of patients' needs, to guide them toward optimal nutrition recommendations, aimed at preventing tumor recurrence and increasing survival rates.
Material And Methods: The cross-sectional web-based survey "Nutrition and breast cancer, what would you like to know?" has been conceived and conducted, in Italy, between the 2nd and the 25th of June 2023.
Phys Imaging Radiat Oncol
October 2024
Mater Olbia Hospital, Department of Medical Physics, Olbia, (SS), Italy.
JMIR Res Protoc
October 2024
see Authors' Contributions, .
Front Oncol
September 2024
Department of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Cancer Treat Rev
November 2024
Division of Thoracic Oncology, European Institute of Oncology IRCCS, Via G. Ripamonti, 435 - 20141 Milan, Italy.
Third-generation EGFR tyrosine kinase inhibitor (TKIs) have revolutionized the treatment landscape for patients with non-small cell lung cancer (NSCLC) harboring EGFR activating mutations, with improved long-term outcomes compared to first-generation TKIs. Nevertheless, disease progression inevitably occurs, limiting osimertinib long-term efficacy. Indeed, the molecular biology underlying acquired resistance to first-line osimertinib is multifaceted and includes the emergence of on-target and off-target alterations.
View Article and Find Full Text PDFGynecol Oncol
December 2024
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Mayo Clinic, Rochester, MN, USA. Electronic address:
Objective: Textbook oncologic outcome (TOO) has been validated in surgical oncology as a composite quality measure correlated with oncologic outcomes. We aimed to assess the association between TOO and overall survival (OS) in patients undergoing primary treatment for advanced epithelial tubo-ovarian cancer (AEOC).
Methods: Patients undergoing surgery for AEOC between 2008 and 2019 were identified in the National Cancer Database (NCDB).
Commun Biol
October 2024
Department of Physics and Astronomy "Ettore Majorana", University of Catania, Catania, Italy.
To understand how oncogenes affect genome organization, it is essential to visualize fundamental processes such as DNA replication and transcription at high resolution in intact cells. At the same time, it is important to determine the progression of the cell along the cell cycle, as cell cycle regulation is crucial for the control of cell proliferation and oncogenesis. Here, we present a super-resolution imaging-based method to analyze single cell nuclei sorted according to specific phases of the cell cycle.
View Article and Find Full Text PDFHaematologica
October 2024
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna.
We evaluated response to VEN/HMA in 46 patients with acute myeloid leukemia (AML) characterized by extramedullary disease (EMD). Median age was 65 (range, 19-81) years. Patients had a median of two EMD sites (range, 1-5) and 35 (76%) patients had concurrent bone marrow involvement.
View Article and Find Full Text PDFExpert Opin Biol Ther
October 2024
Early Drug Development for Innovative Therapies, European Institute of Oncology IRCCS, Milan, Italy.
Introduction: Novel compounds have entered the triple-negative breast cancer (TNBC) treatment algorithm, namely immune checkpoints inhibitors (ICIs), PARP inhibitors and antibody-drug conjugates (ADCs). The optimization of treatment efficacy can be enhanced with the use of combination treatments, and the incorporation of novel compounds. In this review, we discuss the combination treatments under development for the treatment of TNBC.
View Article and Find Full Text PDFESMO Open
October 2024
Early Drug Development for Innovative Therapies, European Institute of Oncology IRCCS, Milan; Department of Oncology and Hemato-Oncology, University of Milan, Milan. Electronic address:
Background: Somatic genetic alterations of the estrogen receptor 1 gene (ESR1) are enriched in endocrine therapy-resistant, estrogen receptor-positive (ER+) metastatic breast cancer (mBC). Herein, we investigated and compared the clinical and genomic landscape of ESR1-mutant (ESR1) and ESR1 wild type (ESR1) ER+/ human epidermal growth factor receptor 2 (HER2)- mBCs.
Methods: Clinical and genomic data were retrieved from cBioPortal using the publicly-available MSK MetTropism dataset.
Arch Ital Urol Androl
October 2024
Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genoa.
Target Oncol
November 2024
Medical Oncology Unit, Macerata Hospital, Macerata, Italy.
Neuro Oncol
December 2024
Unit of Radiation Research, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Minerva Endocrinol (Torino)
September 2024
Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada.
Background: The use of inpatient palliative care (IPC) in advanced cancer patients represents a well-established guideline recommendation. This study examines the utilization rates and patterns of IPC among patients with metastatic adrenocortical carcinoma (mACC).
Methods: Relying on the Nationwide Inpatient Sample database (2007-2019), we tabulated IPC rates in mACC patients.